• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌患者血清中miR-21、HSP90a和gGASP-1的表达及其与病理亚型的相关性。

The expression of miR-21, HSP90a and gGASP-1 in serum of patients with lung cancer and their correlation with pathological subtypes.

作者信息

Pang Hongyan, Gong Yange, Wang Yaojie, Zhang Lianyong

机构信息

Cangzhou Central Hospital, Department of Respiratory and Critical Care Medicine, Cangzhou, China.

出版信息

J Med Biochem. 2024 Jun 15;43(4):460-468. doi: 10.5937/jomb0-48051.

DOI:10.5937/jomb0-48051
PMID:39139173
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11318063/
Abstract

BACKGROUND

To investigate the expression of miR-21, heat shock protein-90a (HSP90a) and G protein-coupled receptorrelated sorting protein 1(GASP-1) in the serum of lung cancer patients and their correlation with pathological subtypes.

METHODS

Eighty patients with lung cancer were included in the lung cancer group from May 2020 to May 2022, and 40 volunteers who underwent physical examination were randomly included in the control group according to the group ratio of 2:1. This ratio balances the need for a sufficiently large experimental group to detect significant effects with the practicality of recruiting a manageable control group. To ensure the validity of our findings, we meticulously calculated the sample size to achieve adequate statistical power, thus enabling us to draw reliable conclusions. Serum miR-21, HSP90a and GASP-1 levels of patients in the two groups were detected. We quantitatively assessed the serum levels of miR-21, HSP90a, and GASP1 in lung cancer patients and healthy volunteers. We employed enzyme-linked immunosorbent assay (ELISA) for HSP90a and GASP-1, and reverse transcription-polymerase chain reaction (RT-PCR) for miR-21, ensuring precise quantification. To explore the correlation between it and pathological subtypes, TNM stage and lymph node metastasis of lung cancer patients. TNM stands for Tumor, Node, and Metastasis. This system is widely used for staging cancer and describes the size and extent of the primary tumor (T), the absence or presence of cancer in nearby lymph nodes (N), and whether the cancer has spread to other parts of the body (M).

RESULTS

The serum levels of miR-21, HSP90a and GASP1 in lung cancer group were higher than those in control group (P < 0.05). ROC curve analysis showed that serum miR-21, HSP90a and GASP-1 levels had certain value in the diagnosis of lung cancer, and their AUC values were 0.901, 0.874 and 0.865, respectively (P < 0.05). There was no difference in the relative expression level of serum miR-21 between squamous cell carcinoma group and adenocarcinoma group (P>0.05), but the levels of HSP90a and GASP-1 in adenocarcinoma group were higher than those in squamous cell carcinoma group (P < 0.05). There was no difference in the levels of serum miR-21, HSP90a and GASP-1 between stage I and stage II groups (P>0.05). The levels of serum miR-21, HSP90a and GASP-1 in stage III and stage IV groups were higher than those in stage I and stage II groups, and those in stage IV were higher than those in stage III group (P < 0.05). The serum levels of miR-21, HSP90a and GASP-1 in patients with metastasis were higher than those in patients without metastasis (P < 0.05).

CONCLUSIONS

Our study concludes that there is a notable association between elevated serum levels of miR-21, HSP90a, and GASP-1 and lung cancer. However, it is crucial to acknowledge that these findings are preliminary and further statistical analysis is needed to strengthen these associations. Future studies with comprehensive statistical evaluation will be vital to validate these potential biomarkers for lung cancer diagnosis and prognosis.

摘要

背景

探讨肺癌患者血清中 miR-21、热休克蛋白 90a(HSP90a)和 G 蛋白偶联受体相关分选蛋白 1(GASP-1)的表达及其与病理亚型的相关性。

方法

2020 年 5 月至 2022 年 5 月纳入肺癌组肺癌患者 80 例,按 2∶1 的组间比例随机纳入 40 例体检志愿者作为对照组。该比例平衡了需要足够大的实验组以检测显著效应与招募可管理对照组的实际可行性。为确保研究结果的有效性,我们精心计算了样本量以获得足够的统计效力,从而使我们能够得出可靠的结论。检测两组患者血清 miR-21、HSP90a 和 GASP-1 水平。我们定量评估了肺癌患者和健康志愿者血清中 miR-21、HSP90a 和 GASP1 的水平。我们采用酶联免疫吸附测定(ELISA)检测 HSP90a 和 GASP-1,采用逆转录-聚合酶链反应(RT-PCR)检测 miR-21,以确保精确定量。探讨其与肺癌患者病理亚型、TNM 分期及淋巴结转移的相关性。TNM 代表肿瘤、淋巴结和转移。该系统广泛用于癌症分期,描述原发性肿瘤的大小和范围(T)、附近淋巴结中有无癌症(N)以及癌症是否已扩散至身体其他部位(M)。

结果

肺癌组血清 miR-21、HSP90a 和 GASP1 水平高于对照组(P<0.05)。ROC 曲线分析显示,血清 miR-21、HSP90a 和 GASP-1 水平在肺癌诊断中有一定价值,其 AUC 值分别为 0.901、0.874 和 0.865(P<0.05)。鳞状细胞癌组与腺癌组血清 miR-21 相对表达水平差异无统计学意义(P>0.05),但腺癌组 HSP90a 和 GASP-1 水平高于鳞状细胞癌组(P<0.05)。Ⅰ期和Ⅱ期组血清 miR-21、HSP90a 和 GASP-1 水平差异无统计学意义(P>0.05)。Ⅲ期和Ⅳ期组血清 miR-21、HSP90a 和 GASP-1 水平高于Ⅰ期和Ⅱ期组,Ⅳ期高于Ⅲ期组(P<0.05)。有转移患者血清 miR-21、HSP90a 和 GASP-1 水平高于无转移患者(P<0.05)。

结论

我们的研究得出结论,血清 miR-21、HSP90a 和 GASP-1 水平升高与肺癌之间存在显著关联。然而,必须承认这些发现是初步的,需要进一步的统计分析来加强这些关联。未来进行全面统计评估的研究对于验证这些潜在的肺癌诊断和预后生物标志物至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/8d80ddde2302/jomb-43-3-2403460P_g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/c76a767db8f6/jomb-43-3-2403460P_g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/1cb88c5aec77/jomb-43-3-2403460P_g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/8d80ddde2302/jomb-43-3-2403460P_g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/c76a767db8f6/jomb-43-3-2403460P_g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/1cb88c5aec77/jomb-43-3-2403460P_g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28a1/11318063/8d80ddde2302/jomb-43-3-2403460P_g004.jpg

相似文献

1
The expression of miR-21, HSP90a and gGASP-1 in serum of patients with lung cancer and their correlation with pathological subtypes.肺癌患者血清中miR-21、HSP90a和gGASP-1的表达及其与病理亚型的相关性。
J Med Biochem. 2024 Jun 15;43(4):460-468. doi: 10.5937/jomb0-48051.
2
Clinical significance of serum dynamics of HSP90a level in esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.根治性放化疗治疗的食管鳞状细胞癌患者血清HSP90a水平动态变化的临床意义
Cancer Biomark. 2017;19(2):185-192. doi: 10.3233/CBM-160502.
3
Expression of miR-590 in lung cancer and its correlation with prognosis.miR-590在肺癌中的表达及其与预后的相关性。
Oncol Lett. 2018 Feb;15(2):1753-1757. doi: 10.3892/ol.2017.7497. Epub 2017 Nov 28.
4
The Value of Serum Exosomal miR-184 in the Diagnosis of NSCLC.血清外泌体 miR-184 在 NSCLC 诊断中的价值。
J Healthc Eng. 2022 Apr 11;2022:9713218. doi: 10.1155/2022/9713218. eCollection 2022.
5
G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer.G 蛋白偶联受体相关分拣蛋白 1(GASP-1),乳腺癌的一种潜在生物标志物。
Exp Mol Pathol. 2011 Oct;91(2):608-13. doi: 10.1016/j.yexmp.2011.06.015. Epub 2011 Jul 23.
6
Clinical Value of Serum and Exhaled Breath Condensate miR-186 and IL-1β Levels in Non-Small Cell Lung Cancer.血清和呼出气冷凝液 miR-186 和 IL-1β 水平在非小细胞肺癌中的临床价值。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820947490. doi: 10.1177/1533033820947490.
7
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.采用微阵列和 RT-qPCR 评估 miR-198-5p 在肺鳞癌中的临床价值。
World J Surg Oncol. 2018 Feb 2;16(1):22. doi: 10.1186/s12957-018-1320-y.
8
Circulating hsa_circ_0072309, acting via the miR-100/ACKR3 pathway, maybe a potential biomarker for the diagnosis, prognosis, and treatment of brain metastasis from non-small-cell lung cancer.循环中的hsa_circ_0072309通过miR-100/ACKR3途径发挥作用,可能是非小细胞肺癌脑转移诊断、预后和治疗的潜在生物标志物。
Cancer Med. 2023 Sep;12(17):18005-18019. doi: 10.1002/cam4.6371. Epub 2023 Jul 26.
9
Correlations of the MiR-330 expression with the pathogenesis and prognosis of breast cancer.miR-330 的表达与乳腺癌发病机制和预后的相关性。
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1584-1590. doi: 10.26355/eurrev_201902_17117.
10
Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.血清 microRNA-22 和 microRNA-126 水平对非小细胞肺癌发生和转移的预测价值:一项病例对照研究。
Neoplasma. 2017;64(3):453-459. doi: 10.4149/neo_2017_317.

引用本文的文献

1
MicroRNA‑21: A potential therapeutic target in lung cancer (Review).微小RNA-21:肺癌潜在的治疗靶点(综述)
Int J Oncol. 2025 Aug;67(2). doi: 10.3892/ijo.2025.5773. Epub 2025 Jul 11.

本文引用的文献

1
Two co-inherited SNPs of the telomerase reverse transcriptase (TERT) gene are associated with Iraqi patients with lung cancer.端粒酶逆转录酶(TERT)基因的两个共同遗传的单核苷酸多态性(SNP)与伊拉克肺癌患者相关。
J Med Biochem. 2023 Oct 27;42(4):694-705. doi: 10.5937/jomb0-41553.
2
Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil.肿瘤微环境中的细胞动力学以及肺癌的进展强调了中性粒细胞的空间和进化异质性。
Clin Transl Med. 2023 Jul;13(7):e1340. doi: 10.1002/ctm2.1340.
3
Differentiating Thyroid Follicular Adenoma from Follicular Carcinoma via G-Protein Coupled Receptor-Associated Sorting Protein 1 (GASP-1).
通过G蛋白偶联受体相关分选蛋白1(GASP-1)鉴别甲状腺滤泡性腺瘤与滤泡癌
Cancers (Basel). 2023 Jun 29;15(13):3404. doi: 10.3390/cancers15133404.
4
Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis.术前中性粒细胞与淋巴细胞比值与恶性胸膜间皮瘤患者免疫细胞中的 PD-L1 表达相关,并可预测预后。
Sci Rep. 2023 Mar 31;13(1):5263. doi: 10.1038/s41598-023-31448-4.
5
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.非小细胞肺癌中增强程序性细胞死亡蛋白 1 或程序性死亡配体 1 抑制剂敏感性和克服耐药性的新兴治疗策略。
Cancer. 2023 May 1;129(9):1319-1350. doi: 10.1002/cncr.34683. Epub 2023 Feb 27.
6
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.度伐利尤单抗联合或不联合替西木单抗联合化疗作为转移性非小细胞肺癌一线治疗的 III 期 POSEIDON 研究。
J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3.
7
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer.帕博利珠单抗作为晚期非小细胞肺癌一线治疗时,生存与极高和高程序性死亡受体配体1(PD-L1)表达之间的关联
Clin Lung Cancer. 2022 Dec;23(8):731-736. doi: 10.1016/j.cllc.2022.07.003. Epub 2022 Jul 22.
8
G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker, promotes proliferation and invasion of triple negative breast cancer.G 蛋白偶联受体相关分拣蛋白 1(GASP-1),一种普遍存在的肿瘤标志物,可促进三阴性乳腺癌的增殖和侵袭。
Exp Mol Pathol. 2022 Apr;125:104751. doi: 10.1016/j.yexmp.2022.104751. Epub 2022 Feb 2.
9
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with infection.抗程序性细胞死亡蛋白1单克隆抗体免疫疗法治疗合并感染的肺癌的安全性和有效性
Transl Lung Cancer Res. 2021 Oct;10(10):3929-3942. doi: 10.21037/tlcr-21-524.
10
Lung Cancer Screening Quality Criteria: A Population Perspective.肺癌筛查质量标准:人群视角
Chest. 2021 Oct;160(4):e329-e331. doi: 10.1016/j.chest.2021.05.006.